ES2173171T3 - Antagonistas del factor de activacion de plaquetas: indoles de imidazopiridina. - Google Patents

Antagonistas del factor de activacion de plaquetas: indoles de imidazopiridina.

Info

Publication number
ES2173171T3
ES2173171T3 ES95904287T ES95904287T ES2173171T3 ES 2173171 T3 ES2173171 T3 ES 2173171T3 ES 95904287 T ES95904287 T ES 95904287T ES 95904287 T ES95904287 T ES 95904287T ES 2173171 T3 ES2173171 T3 ES 2173171T3
Authority
ES
Spain
Prior art keywords
paf
antagonists
platquets
imidazopiridine
indoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95904287T
Other languages
English (en)
Inventor
James B Summers Jr
Steven K Davidsen
Michael L Curtin
H Robin Heyman
George S Sheppard
Lianhong Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2173171T3 publication Critical patent/ES2173171T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA (I) Y LAS SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS MISMOS QUE SON POTENTES ANTAGONISTAS DEL PAF Y SON UTILES EN EL TRATAMIENTO DE LAS ENFERMEDADES RELACIONADAS CON EL PAF INCLUYENDO EL ASMA, EL SOCK, EL SINDROME DE DOLOR RESPIRATORIO, LA INFLAMACION AGUDA, EL RECHAZO DE ORGANOS TRASPLANTADOS, LAS ULCERAS GASTROINTESTINALES, LAS ENFERMEDADES ALERGICAS DE LA PIEL, LA INMUNIDAD CELULAR RETARDADA, EL PARTO, LA MADURACION FETAL DEL PULMON, Y LA DIFERENCIACION CELULAR.
ES95904287T 1993-12-16 1994-12-08 Antagonistas del factor de activacion de plaquetas: indoles de imidazopiridina. Expired - Lifetime ES2173171T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16856493A 1993-12-16 1993-12-16
US32463194A 1994-10-18 1994-10-18
US08/347,528 US5486525A (en) 1993-12-16 1994-12-05 Platelet activating factor antagonists: imidazopyridine indoles

Publications (1)

Publication Number Publication Date
ES2173171T3 true ES2173171T3 (es) 2002-10-16

Family

ID=27389538

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95904287T Expired - Lifetime ES2173171T3 (es) 1993-12-16 1994-12-08 Antagonistas del factor de activacion de plaquetas: indoles de imidazopiridina.

Country Status (13)

Country Link
US (1) US5486525A (es)
EP (1) EP0734386B1 (es)
JP (1) JPH09507474A (es)
KR (1) KR960706494A (es)
AT (1) ATE212992T1 (es)
AU (1) AU690620B2 (es)
CA (1) CA2176247A1 (es)
DE (1) DE69429827T2 (es)
DK (1) DK0734386T3 (es)
ES (1) ES2173171T3 (es)
IL (1) IL111963A0 (es)
PT (1) PT734386E (es)
WO (1) WO1995016687A1 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2990042B2 (ja) 1994-06-06 1999-12-13 吉富製薬株式会社 新規縮合環カルボン酸誘導体またはその塩、およびその医薬用途
US5753664A (en) * 1995-03-16 1998-05-19 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
GB9508748D0 (en) * 1995-04-28 1995-06-14 British Biotech Pharm Benzimidazole derivatives
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
AU4400597A (en) * 1996-10-08 1998-05-05 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US5811425A (en) * 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001032621A1 (en) * 1999-10-29 2001-05-10 Wakunaga Pharmaceutical Co., Ltd. Novel indole derivatives and drugs containing the same as the active ingredient
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
CN100567266C (zh) * 2001-11-14 2009-12-09 先灵公司 类大麻苷受体配体
US7528165B2 (en) * 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US7632955B2 (en) * 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
DK1474425T3 (da) * 2002-01-07 2006-09-25 Eisai Co Ltd Deazapuriner og anvendelser deraf
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
DE60319714T2 (de) 2002-06-19 2009-04-02 Schering Corp. Agonisten des cannabinoidrezeptors
US6906096B2 (en) * 2002-06-28 2005-06-14 Irm Llc 4,7-Disubstituted indoles and methods of making
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
US20070232681A1 (en) * 2003-10-14 2007-10-04 Oxagen Limited Compounds Having Crth2 Antagonist Activity
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
EP2161273B1 (en) * 2003-12-22 2015-04-15 K.U.Leuven Research & Development Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
BRPI0513811A (pt) * 2004-07-27 2008-07-15 Gilead Sciences Inc imidazo [4,5-d] pirimidinas, seus usos e processos de preparação
NZ556624A (en) * 2004-12-21 2010-06-25 Gilead Sciences Inc 5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and method of antiviral treatment
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
US7645752B2 (en) 2006-01-13 2010-01-12 Wyeth Llc Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
JP2009538289A (ja) * 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
KR101143596B1 (ko) * 2006-07-07 2012-05-11 길리애드 사이언시즈, 인코포레이티드 신규의 피리다진 화합물 및 이의 용도
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MY172424A (en) * 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2606031B1 (en) 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
EP2714680B1 (en) 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
JP2016145155A (ja) * 2013-04-30 2016-08-12 日本農薬株式会社 フタルアミド誘導体及び該誘導体を含有する農園芸用殺虫剤並びにその使用方法
GB201321735D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
WO2016205590A1 (en) * 2015-06-18 2016-12-22 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
KR20180026459A (ko) 2015-06-18 2018-03-12 세파론, 인코포레이티드 1,4-치환된 피페리딘 유도체
CN108349920A (zh) * 2015-09-17 2018-07-31 微麦德斯公司 呋喃醛上的氧化化学
EP3774767B1 (en) * 2018-04-05 2025-10-29 Beth Israel Deaconess Medical Center, Inc. Aryl hydrocarbon receptor modulators and uses thereof
CN115745864B (zh) 2021-09-03 2025-10-10 深圳零一生命科技有限责任公司 吲哚类化合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH574441A5 (es) * 1973-06-14 1976-04-15 Ciba Geigy Ag
DE3200705A1 (de) * 1982-01-13 1983-07-21 Agfa-Gevaert Ag, 5090 Leverkusen Farbfotografisches aufzeichnungsmaterial
PH23498A (en) * 1984-08-06 1989-08-16 Sterling Drug Inc 3-carbonyl-1-aminoalkyl-1h-indoles,composition and use thereof
US5068234A (en) * 1990-02-26 1991-11-26 Sterling Drug Inc. 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
US5120749A (en) * 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
IE922293A1 (en) * 1991-07-17 1993-01-27 Abbott Lab Platelet activating factor antagonists

Also Published As

Publication number Publication date
PT734386E (pt) 2002-07-31
KR960706494A (ko) 1996-12-09
IL111963A0 (en) 1995-03-15
CA2176247A1 (en) 1995-06-22
US5486525A (en) 1996-01-23
AU1303695A (en) 1995-07-03
ATE212992T1 (de) 2002-02-15
DE69429827D1 (de) 2002-03-21
WO1995016687A1 (en) 1995-06-22
DE69429827T2 (de) 2002-11-21
EP0734386B1 (en) 2002-02-06
AU690620B2 (en) 1998-04-30
JPH09507474A (ja) 1997-07-29
DK0734386T3 (da) 2002-05-27
EP0734386A1 (en) 1996-10-02

Similar Documents

Publication Publication Date Title
ES2173171T3 (es) Antagonistas del factor de activacion de plaquetas: indoles de imidazopiridina.
ES2164240T3 (es) Derivados de indol-3-carbonilo y 3-indol-3-sulfonilo como antagonistas del factor activante de plaquetas.
CA2434277A1 (en) Substituted alkylamine derivatives and methods of use
CA2534571A1 (en) Substituted isoquinoline derivatives and methods of use
CA2534570A1 (en) Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
YU90901A (sh) Biciklični heterocikli, lekovi koji sadrže ta jedinjenja, njihova primena i postupci za njihovo pripremanje
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
TW200504069A (en) Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors
WO2002068406A3 (en) Substituted amine derivatives and their use for the treatment of angiogenesis
NO940874L (no) 5-HT4 reseptor-antagonister
EP2165708A3 (en) New pyrazole derivatives as transforming growth factor (TGF) inhibitors
ATE214929T1 (de) Verwendung von 7-(2-oxa-5,8-diazabicyclo 4.3.0)non-8-yl)-chinoloncarbonsäure- und - naphthyridoncarbonsäure-derivaten zur herstellung eines arzneimittels zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
ES2090081T3 (es) Derivados de indolocarbazol, procedimientos para su obtencion y su empleo.
SE9900833D0 (sv) Novel combination
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
ES2131530T3 (es) Antagonistas del factor de activacion de las plaquetas.
MX9207216A (es) Aductos de etanol de 3-hidroxicromanos 6-sulfonil sustituidos y su empleo como agentes de inhalacion de enfermedades.
SE9901273D0 (sv) Novel compounds
NO20062805L (no) Novel indeno (2,1A) indenes and isoindol (2,1-A) indles
MX8232A (es) Derivados de triazolopirimidina.
CA2060333A1 (en) Use of pyrimido-benzothiazine derivatives

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 734386

Country of ref document: ES